Remdesivir diphosphate – CAS 1911578-77-2

Remdesivir diphosphate – CAS 1911578-77-2 is synthesised by Sigut Labs (Prague, Czech Republic).

Purity (LC-MS)

99%+

Package contents

Remdesivir diphosphate Et3NH+ salt

This compound is for research use only. We do not sell to patients.

Amount
1 mg
€ 2500

Stock

5 mg
€ 3500

Stock

Do you want custom amount?
Custom amount
Amount
1 mg
€ 2500

Stock

5 mg
€ 3500

Stock

Do you want custom amount?
Custom amount

Characterisation

CAS: 1911578-77-2
IUPAC name: 2-C-(4-Aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2,5-anhydro-D-altrononitrile 6-diphosphate
Other names: GS-441524 diphosphate, Remdesivir metabolite
Molecular weight: 451.22 g/mol,  653.61 g/mol (Et3NH+ salt)
Molecular formula: C12H15N5O10P2
InChI: InChI=1S/C12H15N5O10P2/c13-4-12(8-2-1-6-11(14)15-5-16-17(6)8)10(19)9(18)7(26-12)3-25-29(23,24)27-28(20,21)22/h1-2,5,7,9-10,18-19H,3H2,(H,23,24)(H2,14,15,16)(H2,20,21,22)/t7?,9-,10+,12-/m0/s1
Storage: -20 °C, protect from light, stored under argon

Description

Remdesivir diphosphate is synthesised by Sigut Labs (Prague, Czech Republic). 

Remdesivir, developed by Gilead Sciences, is an adenosine prodrug that metabolizes into its active form GS-441524 which interferes with the action of viral RNA-dependent RNA polymerase and evades proofreading by viral exoribonuclease (ExoN), causing a decrease in viral RNA production. 

 

Chemicals are distributed worldwide

Buy Remdesivir diphosphate now, get your order in 48 hours.

  • Shipping through DHL in 48 hours
  • Sensitive compounds are shipped on dry ice
  • All compounds are safely and rigorously packed

Payment

  • Payment terms 30 days net
  • We are sending the invoice the same day as the shipment
  • We are able to modify the invoice for the academic institution, so the order can be paid from grants

References

  • Shannon, A.; Le, N. T.-T.; Selisko, B.; Eydoux, C.; Alvarez, K.; Guillemot, J.-C.; Decroly, E.; Peersen, O.; Ferron, F.; Canard, B., Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites. Antiviral Res. 2020, 178, 104793.
  • Ju, J.; Li, X.; Kumar, S.; Jockusch, S.; Chien, M.; Tao, C.; Morozova, I.; Kalachikov, S.; Kirchdoerfer, R. N.; Russo, J. J., Nucleotide analogues as inhibitors of SARS-CoV polymerase. bioRxiv 2020, 1-18.
  • Jordan, P. C.; Liu, C.; Raynaud, P.; Lo, M. K.; Spiropoulou, C. F.; Symons, J. A.; Beigelman, L.; Deval, J., Initiation, extension, and termination of RNA synthesis by a paramyxovirus polymerase. PLoS Pathogens 2018, 14 (2), e1006889/1-e1006889/23.
  • Siegel, D.; Hui, H. C.; Doerffler, E.; Clarke, M. O.; Chun, K.; Zhang, L.; Neville, S.; Carra, E.; Lew, W.; Ross, B.; Wang, Q.; Wolfe, L.; Jordan, R.; Soloveva, V.; Knox, J.; Perry, J.; Perron, M.; Stray, K. M.; Barauskas, O.; Feng, J. Y.; Xu, Y.; Lee, G.; Rheingold, A. L.; Ray, A. S.; Bannister, R.; Strickley, R.; Swaminathan, S.; Lee, W. A.; Bavari, S.; Cihlar, T.; Lo, M. K.; Warren, T. K.; Mackman, R. L., Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. J. Med. Chem. 2017, 60 (5), 1648-1661.
  • Clarke, M. O. N. H.; Jordan, R.; Mackman, R. L.; Ray, A. S.; Siegel, D. Preparation of amino acid-containing nucleosides for treating flaviviridae virus infections. 2017-US28243, 2017184668, 20170419., 2017.
  • Warren, T. K.; Jordan, R.; Lo, M. K.; Ray, A. S.; Mackman, R. L.; Soloveva, V.; Siegel, D.; Perron, M.; Bannister, R.; Hui, H. C.; Larson, N.; Strickley, R.; Wells, J.; Stuthman, K. S.; Van Tongeren, S. A.; Garza, N. L.; Donnelly, G.; Shurtleff, A. C.; Retterer, C. J.; Gharaibeh, D.; Zamani, R.; Kenny, T.; Eaton, B. P.; Grimes, E.; Welch, L. S.; Gomba, L.; Wilhelmsen, C. L.; Nichols, D. K.; Nuss, J. E.; Nagle, E. R.; Kugelman, J. R.; Palacios, G.; Doerffler, E.; Neville, S.; Carra, E.; Clarke, M. O.; Zhang, L.; Lew, W.; Ross, B.; Wang, Q.; Chun, K.; Wolfe, L.; Babusis, D.; Park, Y.; Stray, K. M.; Trancheva, I.; Feng, J. Y.; Barauskas, O.; Xu, Y.; Wong, P.; Braun, M. R.; Flint, M.; McMullan, L. K.; Chen, S.-S.; Fearns, R.; Swaminathan, S.; Mayers, D. L.; Spiropoulou, C. F.; Lee, W. A.; Nichol, S. T.; Cihlar, T.; Bavari, S., Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature (London, United Kingdom) 2016, 531 (7594), 381-385.
  • Chun, B. K.; Clarke, M. O. N. H.; Doerffler, E.; Hui, H. C.; Jordan, R.; Mackman, R. L.; Parrish, J. P.; Ray, A. S.; Siegel, D. Preparation of nucleosides and methods for treating Filoviridae virus infections. 2015-14926062 20160122374, 20151029., 2016.
  • Cho, A.; Saunders, O. L.; Butler, T.; Zhang, L.; Xu, J.; Vela, J. E.; Feng, J. Y.; Ray, A. S.; Kim, C. U., Synthesis and antiviral activity of a series of 1′-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. Bioorganic & Medicinal Chemistry Letters 2012, 22 (8), 2705-2707.
bg molecul blue light

Didn't find the chemical you were looking for?

Contact us
Contact
Kryštof

Get in touch

Krystof Sigut, CEO and Founder

WHY CHOOSE
SigutLabs

Your impossible is our starting line

Located in Prague, Czech Republic, EU
Versatile, seasoned all-PhD team
Global delivery with Silicon Valley clients
Open communication, reliable approach
Verifying quality of all produced substances
95% shipments delivered within 2 days

Partners & distributors

logo partner
logo partner
logo partner
logo partner
logo partner
logo partner
logo partner
logo partner